Novo Nordisk A/S
NVO
$57.20
$1.582.84%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.48% | 22.67% | 24.86% | 27.74% | 31.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.48% | 22.67% | 24.86% | 27.74% | 31.76% |
| Cost of Revenue | 25.09% | 24.10% | 23.21% | 22.41% | 29.06% |
| Gross Profit | 20.83% | 22.41% | 25.16% | 28.74% | 32.26% |
| SG&A Expenses | 14.38% | 9.26% | 9.22% | 14.78% | 14.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -157.84% | -682.42% | -8.33% | 92.85% | 50.61% |
| Total Operating Expenses | 18.45% | 16.46% | 17.85% | 21.15% | 24.79% |
| Operating Income | 25.00% | 30.05% | 33.41% | 36.22% | 40.92% |
| Income Before Tax | 25.18% | 16.90% | 21.44% | 29.07% | 38.99% |
| Income Tax Expenses | 29.54% | 21.18% | 24.76% | 37.11% | 46.61% |
| Earnings from Continuing Operations | 24.06% | 15.82% | 20.61% | 27.14% | 37.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.06% | 15.82% | 20.61% | 27.14% | 37.16% |
| EBIT | 25.00% | 30.05% | 33.41% | 36.22% | 40.92% |
| EBITDA | 26.38% | 29.01% | 31.20% | 33.57% | 38.99% |
| EPS Basic | 24.60% | 16.43% | 21.37% | 28.09% | 38.34% |
| Normalized Basic EPS | 22.46% | 25.45% | 30.62% | 36.58% | 47.49% |
| EPS Diluted | 24.77% | 16.56% | 21.47% | 28.16% | 38.32% |
| Normalized Diluted EPS | 22.55% | 25.55% | 30.71% | 36.67% | 47.57% |
| Average Basic Shares Outstanding | -0.43% | -0.54% | -0.64% | -0.78% | -0.90% |
| Average Diluted Shares Outstanding | -0.52% | -0.62% | -0.72% | -0.85% | -0.96% |
| Dividend Per Share | 18.93% | 19.95% | 19.95% | 43.18% | 43.18% |
| Payout Ratio | -0.04% | 0.03% | 0.16% | 0.10% | 0.13% |